이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

HMA 기반 요법에 실패한 고위험 MDS 또는 AML 환자에서 Imetelstat를 평가하기 위한 연구 (IMpress)

2026년 9월 10일 업데이트: GCP-Service International West GmbH

HMA 기반 요법에 실패한 HR 골수이형성 증후군 또는 AML 환자에서 Imetelstat의 효능 및 안전성을 평가하는 2상 연구

The purpose of this study is to evaluate the efficacy, in terms of hematologic improvement, and safety of imetelstat in participants with high-risk (HR) myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that is relapsed/refractory to hypomethylating agents (HMAs) treatment. Responding patients are eligible to continue treatment until loss of response/disease progression.

연구 개요

연구 유형

중재적

등록 (실제)

46

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Düsseldorf, 독일
        • Marien Hospital Düsseldorf
      • Jena, 독일
        • Universität Jena, Medizinische Fakultät
      • Leipzig, 독일
        • Universität Leipzig, Medizinische Fakultät
      • München, 독일
        • Klinikum rechts der Isar
      • Nantes, 프랑스
        • CHU Nantes - Hôtel Dieu
      • Nice, 프랑스
        • Hôpital Archet 1
      • Paris, 프랑스
        • Hôpital Saint-Louis
      • Toulouse, 프랑스
        • CHU de Toulouse
      • Adelaide, 호주
        • Royal Adelaide Hospital
      • Brisbane, 호주
        • Royal Brisbane and Women's Hospitals
      • Nedlands, 호주
        • Linear Clinical Research

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Signed written informed consent
  • Male and female ≥ 18 years at the first screening
  • Must be able to adhere to the study visit schedule and other protocol requirements
  • Initial diagnosis of AML or MDS according to WHO (World Health Organization) 2016 classification
  • At least one cytopenia
  • Failure to achieve complete or partial response or hematological improvement observed after at least six azacitidine monotherapy or four decitabine monotherapy based 4-week treatment cycles administered during the past two years OR Failure to achieve complete or partial response or hematological improvement observed after at least two 4-week treatment cycles with azacitidine plus venetoclax or with decitabine plus venetoclax during the past two years OR Relapse after initial complete or partial response or hematological improvement observed after at least six (azacitidine) or four (decitabine) based 4-week treatment cycles administered during the past two years OR Relapse after initial complete or partial response or hematological improvement observed after at least two 4-week treatment cycles with azacitidine plus venetoclax or with decitabine plus venetoclax during the past two years OR Intolerance to treatment with HMA-based therapy during the past two years
  • Not eligible for allogeneic stem cell transplantation
  • ≥ 5% bone marrow blasts at screening
  • Off all other treatments for AML/MDS for at least 14 days; granulocyte colony-stimulating factor (G-CSF) and erythropoietin are allowed before and during the study as clinically indicated
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Biochemical laboratory test values must be within the defined limits.
  • Availability of blood counts and transfusion events for previous 16 weeks
  • Women of childbearing potential and practicing a highly effective method of birth control consistent with local regulations regarding the use of birth control methods for subjects participating in clinical studies. For females, these restrictions apply for 3 months after the end of dosing.
  • A woman of childbearing potential must have a negative serum or urine pregnancy test at screening and agree to be tested on day 1 of every cycle and at End of Treatment (EOT)
  • A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control. For males, these restrictions apply for 3 months after the end of dosing
  • Patients who are relapsed or refractory to, or not eligible for, therapy with approved and available FLT3 (FMS-like tyrosine kinase 3) or IDH1/IDH2 (Isocitrate dehydrogenase) inhibitors or other approved targeted therapies.

Exclusion Criteria:

  • Chemotherapy within the 14 days prior to the first dose of imetelstat being administered (other than hydroxyurea)
  • Participant has known allergies, hypersensitivity, or intolerance to imetelstat or its excipients (refer to the Investigators Brochure (IB))
  • Participant has received an experimental or investigational drug or used an invasive investigational medical device within 30 days prior to day 1 of Cycle 1
  • Prior treatment with imetelstat
  • Prior history of intensive chemotherapy or hematopoietic stem cell transplant
  • Major surgery within 4 weeks prior to day 1 of Cycle 1 (excluding the placement of vascular access and other minor surgical procedures)
  • Diagnosed or treated for malignancy other than MDS or AML, except:

Malignancy treated with curative intent and with no known active disease present for 3 years before day 1 of Cycle 1 Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease Adequately treated cervical carcinoma in situ without evidence of disease

  • Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of day 1 of Cycle 1, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification
  • Known history of human immunodeficiency virus (HIV) or any uncontrolled active systemic infection requiring IV antibiotics
  • Active systemic hepatitis infection requiring treatment (carriers of hepatitis virus are permitted to enter the study), or known acute or chronic liver disease including cirrhosis
  • Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the participant 's safety, interfere with the imetelstat metabolism, or put the study outcomes at undue risk; Participant has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
  • Females who are pregnant or are currently breastfeeding or planning to become pregnant while enrolled in this study or within 3 months after the end of dosing
  • Participant is a man who plans to father a child while enrolled in this study or within 3 months after the end of dosing
  • Other:

Participant is in custody by order of an authority or a court of law Participation in another interventional clinical study within the last 3 months prior to signing the Informed consent form (ICF) or simultaneous participation in other interventional clinical studies Previous assignment to treatment during this study Close affiliation with the investigator (e.g., a close relative) or persons working at the study site Participant is an employee of the sponsor or involved Contract Research Organization (CRO) Criteria which in the opinion of the investigator preclude participation for scientific reasons, for reasons of compliance, or for reasons of the Participant's safety

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: 단일 암 imetelstat

Intravenous injection

다른 이름들:
  • GRN163L

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Overall Hematological Response Rate of Participants After Treatment With Imetelstat
기간: Up to Week 17 (Visit 9; approximately 17 weeks after first dose).

The combined response assessment criteria for MDS and AML based on IWG (International Working Group) 2018 criteria (MDS) and the criteria of the European LeukemiaNet (AML) will be used to define responders.

The response rate is calculated as number of responders divided by the number of all participants of the analysis set.

Up to Week 17 (Visit 9; approximately 17 weeks after first dose).

2차 결과 측정

결과 측정
측정값 설명
기간
Toxicity Measured by NCI CTCAE v5.0 (National Cancer Institute - Common Terminology Criteria for Adverse Events Version 5.0)
기간: From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject).

Toxicity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. A treatment-emergent adverse event (TEAE) was defined as any adverse event arising or worsening after the first dose of study drug. The number of participants experiencing at least one TEAE was summarized in the Safety Evaluation Set.

From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject).

기타 결과 측정

결과 측정
측정값 설명
기간
Treatment Duration (Days)
기간: From Treatment Start (Cycle 1 Day 1) to End of Treatment (EOT). Duration varies by subject.

The number of days between the first and last doses of study treatment. Subjects who discontinued early have duration calculated to their final dose date.

From Treatment Start (Cycle 1 Day 1) to End of Treatment (EOT). Duration varies by subject.
Treatment Compliance
기간: From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject).

Percentage of study-drug doses received relative to the number of doses planned per protocol.

Computed as: Compliance (%) = (Actual doses received ÷ Planned doses) × 100. Missed or undocumented doses are counted as not received unless justified per protocol or Statistical Analysis Plan (SAP). Dose holds and reductions are included in compliance assessment.

From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject).
Cumulative Dose (mg)
기간: From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject)

Total amount of imetelstat (mg) received across all treatment administrations. Calculated as the sum of all administered doses documented in the dose-administration eCRF (electronic Case Report Form).

Notes: Dose reductions, missed doses, and dose delays are captured in the calculation. Missing dose records default to "not administered" unless clarified.

From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2023년 6월 5일

기본 완료 (실제)

2025년 3월 27일

연구 완료 (실제)

2025년 9월 30일

연구 등록 날짜

최초 제출

2022년 10월 13일

QC 기준을 충족하는 최초 제출

2022년 10월 13일

처음 게시됨 (실제)

2022년 10월 17일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 2일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 10일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다